

[1］Pan CY，Landen H.Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China［J］.Clin Drug Investig，2007，27(6)：397-405. 

[2］杨文英，林立香，齐今吾，等.阿卡波糖和二甲双胍对IGT人群糖尿病预防的效果--多中心3年前瞻性观察［J］.中国内分泌代谢杂志，2001，17(3)：131-134. 

[3］潘长玉，姬秋和，杨文英，等.2型糖尿病患者维格列汀与阿卡波糖单药治疗的比较研究--24周多中心、随机、双盲、双模拟、阳性对照试验［J］.中华内分泌代谢杂志，2009，25(4)：386-390. 

[4］Hanefeld M，Cagatay M，Petrowitsch T，et al.Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients：meta-analysis of seven long-term studies［J］.Eur Heart J，2004，25(1)：10-16. 

[5］Yang WY，Liu J，Shan Z，et al.Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes：an open-label，non-inferiority randomised trial［J］.The Lancet Diabetes & Endocrinology，2014，2(1)：46-55. 

[6］Cani PD，Neyrinck AM，Fava F，et al.Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia［J］.Diabetologia，2007，50(11)：2374-2383. 

[7］许小津，惠宏襄，蔡德鸿，等.2型糖尿病患者与健康个体间肠道双歧杆菌的差异［J］.南方医科大学学报，2012，32(4)：531-533，564. 

[8］刘海霞，李晶，刘奔，等.阿卡波糖对2型糖尿病患者粪便中双歧杆菌数量的影响［J］.中华内分泌代谢杂志，2011，27(11)：928-931. 

[9］Enc FY，Imeryüz N，Akin L，et al.Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release［J］.Am j Physiol Gastrointest Liver Physiol，2001，281：G752-G763. 